Company news

Benitec Biopharma Inc. news in 2025

Benitec Biopharma Inc.'s news releases, calls and decks from 2025, newest first.

View company

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

November 14, 2025

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

November 6, 2025

Benitec Biopharma Inc. Announces Proposed Public Offering

November 5, 2025

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

November 3, 2025

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

November 3, 2025

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy

November 1, 2025

Annual Report for Fiscal Year Ending June 30, 2025 (Form 10-K)

September 23, 2025

Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update

September 22, 2025

Benitec Biopharma Provides Operational Updates

July 9, 2025

Benitec Biopharma Releases Third Quarter 2025 Financial Results

May 14, 2025

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

March 25, 2025

Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

March 19, 2025

Benitec Biopharma to Participate in Upcoming Conferences in March

February 26, 2025

Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update

February 13, 2025

Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference

February 13, 2025

Benitec Biopharma to Participate in Upcoming Conferences in January and February

January 26, 2025

Decks in 2025